Immunotherapy for the Treatment of Breast Cancer: Emerging New Data

Figures & data

Figure 1 History of Breast Cancer Treatment.

Table 1 Landmark Clinical Trials

Trial	Checkpoint Inhibitor	Response	PFS	OS
KEYNOTE-012 (N=27)	Pembrolizumab	ORR 18.5%	1.9 months	11.2 months
KEYNOTE-028 (N=25)	Pembrolizumab	ORR 12%	1.8 months	8.6 months
KEYNOTE-086 Cohort A (N=170, 61.8% PD-L1+)	Pembrolizumab	ORR 4.7% (4.8% for PD-L1+, 4.7% for PD-L1-)	2 months	8.9 months
KEYNOTE-086 Cohort B (N=84)	Pembrolizumab	ORR 23.1%	2.1 months	-
Emens et al (N=115)	Atezolizumab	ORR 10% (12% for PD-L1+, 0% for PD-L1-)	1.4 months	8.9 months
JAVELIN (N=168)	Avelumab	ORR 4.8% (3.3% for PD-L1+, 2.4% for PD-L1-)	5.9 months	8.1 months
IMPASSION 130 (N=912)	Atezolizumab + nab-paclitaxel	ORR 56%	7.2 months (7.5 months for PD-L1+)	21.3 months (25 months for PD-L1+)